A Case of Essential Thrombocythemia Presenting as Esophageal Varix Bleeding and Multiple Thrombosis.
10.12701/yujm.2011.28.1.99
- Author:
So Yeon YOON
1
;
Jun Hyeok CHOI
;
Sun Mi KANG
;
Jung Nam CHO
;
Sung Hwa BAE
;
Hun Mo RYOO
Author Information
1. Division of Hemato-Oncology, Department of Internal Medicine, School of Medicine, Catholic University of Daegu, Republic of Korea. rhmrhm@cu.ac.kr
- Publication Type:Case Report
- Keywords:
Essential thrombocythemia;
Esophageal varix;
Thrombosis;
JAK2
- MeSH:
Blood Platelets;
Esophageal and Gastric Varices;
Hemorrhage;
Humans;
Incidence;
Mesenteric Veins;
Myeloproliferative Disorders;
Portal Vein;
Splenic Vein;
Thrombocythemia, Essential;
Thrombocytosis;
Thrombosis;
TYK2 Kinase;
Varicose Veins
- From:Yeungnam University Journal of Medicine
2011;28(1):99-104
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Essential thrombocythemia (ET), a subcategory of chronic myeloproliferative disorder, is characterized by absolute thrombocytosis due to excessive clonal proliferation of platelets, hyperaggregability of platelets, and increased incidence of thrombosis and hemorrhage. We consider a diagnosis of ET when an unexplained and persistent thrombocytosis is observed. It is difficult to consider ET first when we meet a patient with esophageal varix bleeding or unusual multiple thromboses like mesenteric vein, splenic vein, and portal vein. This article reports a patient who presented initially with esophageal varix bleeding and unusual multiple thromboses, thereafter, she was diagnosed with ET after testing positive for the Janus Tyrosine Kinase 2 (JAK2) V617F mutation. In conclusion, in patients with varix bleeding and unusual multiple thromboses, myeloproliferative disorders like essential thrombocythemia should be considered as a potential cause and testing for the JAK2 mutation is warranted.
